You will know about new technologies and person, who can revolutionize biology !

New Hope For People

People Could Be Already Healed With My Anti-Cancer, Anti-Viral And
Anti-Autoimmune Inventions

Alexander Cherkasky
alexcherkasky@googlemail.com

http://alexandercherkasky.blogspot.com/
http://feasibilityofalexandercherkaskysinven.blogspot.de/
http://cherkaskyoffers.blogspot.com/
http://cherkaskysneweconomicmodel.blogspot.de/
http://likenaturalsyntheticdiamonds.blogspot.de/


My name is Alexander Cherkasky, I am award-winning and
media-highlighted inventor and biologist and my story concerns various
fields including science, economy and general information relating to
all people, especially because my already published inventions can
help people. My inventions can heal. And a number of my inventions was
confirmed and my inventions are feasible and work.
The totality of facts described below is very near to everybody and
this totality of the facts disclosed below is unique. Thus I am
seeking for support for commercial implementation of my proposed
inventions, especially my anti-cancer, anti-viral, anti-autoimmune
inventions, inventions against metabolic disorders, inventions for
prolongation of cell life and extension of human life, renewal of
cells and tissues, regenerations, especially for neural regeneration,
and sequencing and diagnostic inventions, as well as inventions of
novel high-quality like-natural (like-as-natural) synthetic diamonds,
new lubricants and new materials, especially building materials. In
addition to seeking for partners for joint foundations of companies, I
am also seeking for support for establishing the new research
institute for further working on my solutions of biomedical problems.
Interesting is, that certain firms including Micromet, (who wanted to
be a ”future leader”), Merck in Darmstadt (Germany), Bayer, Apogenix,
Halcyon Molecular, Vaxil, Vecoy and ZS Genetics as well as the
organization Deutsches Krebsforschungszentrum (DKFZ, German Cancer
Research Center) are involved in plagiarism, in stealing my inventions
of anti-cancer fusion protein cures, anti-viral therapies and fast
genome sequencing systems.
Micromet, which was listed on the technology stock exchange NASDAQ (as
a public company with ticker symbol MITI) and which is now merged into
Amgen and renamed, ignored my two comments on Google Finance, in
Discussion Group about Micromet, although Micromet was a public
company.
About Micromet’s plagiarism of my anticancer and antiautoimmune
inventions wrote also The New Rhein Newspaper (NRZ) Dusseldorf on
March 26, 2013, also because Micromet was a German company and I
immigrated from Ukraine to Germany in 1996 and I started to invent, to
create theoretical problem solutions (without lab, without working in
a laboratory).
Amgen denied to give any statement to NRW Dusseldorf about its deal
with Micromet, although Amgen is also a public company.
NRZ Dusseldorf wrote also about the plagiarist Apogenix, who stated
and just still continues to state that ”its” anticancer inventions are
”novel”.

I filed my first invention (of targeted genetically engineered
oncolytic viruses with recognizing receptors or antibodies) in the
year 1998, (my German patent application DE19818938), as I was student
at Goethe-Gymnasium (High School) in Dusseldorf.
The New Yorker Nobel Laureate Joshua Lederberg tried to claim this
invention in his US patent application US20040033584, but because I
had and have priority in Germany, which is priority worldwide,
Lederberg’s patent application was not new and not inventive.
The international patent application WO2006119449 for oncolytic
viruses of the American inventor David Curiel is also not novel and
not inventive because of my prior German patent publication
DE19818938.
This my DE19818938 makes also the US patent application US20040247569
”Reduction in bacterial colonization by administering bacteriophage
compositions” of Intralytix, Inc., Baltimore, MD, US, (named inventors
are Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze (Tbilisi,
GE), Gary Pasternack and Torrey Brown; filed: December 2, 2003) not
new and not inventive.
In the years 1999 and 2000 I participated on the scientfic youth
competition ”Jugend forscht” (”Youth researches”) and presented my
inventions of novel anti-Alzheimer, anti-autoimmune and anti-cancer
fusion proteins. It evoked broad interest of press and about me and
inventions of mine reported Stern (The Star, March 25, 1999), Bild der
Wissenschaft (Picture of Science), Westdeutsche Zeitung (Westgerman
Newspaper), Neue Rhein Zeitung (New Rhein Newspaper), Rheinische Post
(Rhein Post) and other media.
”Jugend forscht” or ”Youth researches” was observed by the firm Bayer,
who made obstacles, but paid approximately 300 million euro to the
plagiarist Micromet for my invention presented at ”Youth researches”
in 2000!
For my novel selective anticancer fusion proteins I was awarded the
Bronze Medal ”For Outstanding Achievements” and the Honorary
Certificate of the largest international inventors competition in
Germany IENA (Ideas-Inventions-New Products) 2003 in Nuremberg.
By searches in the data banks of patent literature I discovered, that
a number of my inventions were used, were implemented and confirmed
with success by experiments and in certain cases my name and my
according patent documents were mentioned, refenced and in other cases
my name and my according patent documents were not referenced. The
cases, in which my name and according patent publications are not
referenced, although I have clearly documented priority and
inventorship, are either cases of plagiarism, because the totality of
joint features is obvious and plagiarists are not able to explain the
differences, that would make their ”inventions” new and inventive, or
are cases of insufficient searches in the data banks for patent
literature. Plagiarists are, in this context, persons, who are aware
of my according priority and inventorship, but in despite of this
knowledge, these persons continue to make false statements about
inventorship, but such statements are false, because no arguments or
no evidence were provided by these plagiarists.
Please read the following blogs to learn more:

http://feasibilityofalexandercherkaskysinven.blogspot.de/
http://alexandercherkasky.blogspot.com/
http://cherkaskyoffers.blogspot.com/
http://plagiaristvaxil.blogspot.de/
http://plagiaristzsgenetics.blogspot.de/
http://plagiaristsdkfzandapogenix.blogspot.de/ and
http://plagiaristvecoy.blogspot.de/ .

Interestingly, the US company Halcyon Molecular cited my German
patent DE19937512 for fast genome sequencing in their US patent
US8153438, but Halcyon Molecular did not explained a difference, that
would make their patent , (issued by error of examiner and thus
rejectable after reexamination with the USPTO), new and inventive.
Errors of patent examiners can take place and this is obvious on
illustrative examples of issued US patents US7323440 (of Micromet) for
Fc-Autoantigen, especially Fc-AchR fusion proteins and US8007813
(based on the US patent applications US20070269449 and US20110305697
of Apogenix) for Fc-Receptor and Fc-Ligand fusion proteins, although
all Fc-Autoantigen, Fc-Receptor-Region, Fc-Receptor and Fc-Ligand
fusion proteins are disclosed in my prior patent publication
DE10160248. Because of this my DE10160248 both issued by error of
examiners US patents US7323440 of Micromet and US8007813 of Apogenix
can be reexamined and invalidated/rejected after reexamination by the
USPTO.
Because of my DE10160248 a number of patent documents/patent
applications are not new and not inventive. These published not new
and not inventive patent documents of others include the following:
EP2465524 (European patent application “Autoantibody production
inhibitor” of Nihon Pharmaceuticals in Tokyo (JP) describing
Fc-Autoantigen fusion proteins), WO2012159550 (“FGFR-Fc Fusion Protein
and Use thereof” of Yantai RC Biotechnogies Ltd (CN), Jianmin Fang
(CN), and Dong Li (CN)), NZ591970 (“Fusion Constructs and Use of Same
to Produce Antibodies with Increased Fc Receptor Binding Affinity and
Effector Function” of Pablo Umana, Peter Bruenker, Claudia Ferrara and
Tobias Suter at Roche Glycart AG, (also published as AU2012213963)),
MX2011011044 (“Antibody Fusion Proteins with Modified FcRN Binding
Sites” of Kin-Ming Lo (DE) and Pascal Andre Stein at Merck Patent
GmbH; especially claim 8 describing Fc Fragment), US20120093814
(“Fusion Proteins Comprising Canine FC Portions” of Keith Canada,
Sanjaya Singh, Xiangyang Zhu at Boehringer Ingelheim International
GmbH (DE)), NZ569702 (“Recombinant human EPO-Fc fusion proteins with
prolonged half-life and enhanced erythropoietic activity in vivo” of
Wang Houtao Du Yong et al at Novagen Holding Corp), KR20120028358
(“Truncated ACTR II B-Fc Fusion Proteins” of Seehra Jasbir (US) and
Kumar Ravindra (US) at Acceleron Pharma (US)), KR20120041139 (“Human
Interleukin-1 Receptor Antagonist-Hybrid Fc Fusion Protein” of Handkok
Pharmaceuticals Co Ltd (KR)) and US20120116056 (“Fc fusion proteins of
human growth hormone” of Sun Bill Nai-Chau (CN), Liou Ruey-Shyan (US)
et al).
But known are the cases in which examiners of patent offices done
searches and sent search reports to others, revealing with these
search reports, that my according prior patent documents made and make
claims and descriptions of others not novel and not inventive. For
example, my patent document DE19925052 was sent as search result for
the following patent publications of others: WO03070193 (”RNA
Interference Mediated Inhibition of HIV Gene Expression Using Short
Interfering Nucleic Acid (siNA)” of Sirna Therapeutics Inc. (US),
James McSwiggen (US), Leonid Beigelman (US) and Dennis Macejak (US),
also published as US20030175950, JP2006502694, EP1572128, CA2476394
and AU2003215345), EP1361891 (and WO02/066514 (PCT/EP02/01690))
(”Artifical Fusion Proteins with Reduced Immunogenicity” of Stephen
Gillies (US), Francis Carr (GB), Tim Gones (GB), Graham Carter (GB),
Anita Hamilton (GB), Stephen Williams (GB), Marian Haulon (GB), John
Watkins (GB), Matthew Baker (GB) and Jeffrey Way (US) at Merck Patent
GmbH (DE), (whreby Merck (Patent GmbH) replied to me in 1998 with deny
of cooperation, stating, that my proposed inventions are outside of
Merck’s research focus)), and EP1308516 (”Site-directed Recombinase
Fusion Proteins and Corresponding Polynucleotides, Vectors and Kits
and Their Uses for Site-directed DNA-Recombination” (Filed: October
24, 2001 and published on May 07, 2003) of Ferenc Mueller (DE), Uwe
Straehle (DE), Laszlo Tora (FR), Olasz Ferenc (HU), Janos Kiss (HU)
and Monika Szabo (HU) at Association pour le Developement de la
Recherche en Genetique Moleculaire in Paris). Plagiarism of Apogenix
and German Cancer Reserch Center DKFZ, confirmed by examiners of the
European Patent Office, was descibed in my blog
http://plagiaristsdkfzandapogenix.blogspot.de/.
Examiners sent my DE10162867 as research result concerning the
international patent application WO2006045591 (PCT/EP2005/011441)
“Method and Constructs for Delivery Double Strauded RNA to Pest
Organisms” of Devgen NV (BE), Thierry Andre Olivier Bogaert (BE),
Richard Zwaal (BE), Geert Plaetnik (BE), Jan Octaaf de Kerpel (BE) and
Titus Jan Kaletta (BE).

I have developed programs of inventions including anti-cancer,
anti-autoimmune and anti-viral inventions.
My anticancer inventions (my program including my DE10350122,
DE19925052, DE19818938, DE19922406, DE10160248, DE10161899,
DE10161738, DE10161739, DE10162870, DE10162867, DE10350131,
DE102005028619, WO2006136892, WO2005040382, US20070106066 and
US20080200652) comprise inventions which allow to modify cancer cells
in order to normalize or combat them by acting on cytoskeleton,
cytoxically and/or by attracting T cells against target cells. In
addition, the effects of the anti-cancer antibodies which are already
on the market can be boosted by using my novel antibody-binding fusion
proteins. Damaged tissue can be regenerated with my inventions of
genetically modified cells expressing regeneration and genesis
proteins (my published German patent document DE19951694).
Because of my DE19925052, DE10161738 and DE10162870 covering novel
cytotoxic fusion proteins, the international patent application
WO2005116221 for immune suppressive hCTLA4-Ig (human cytotoxic T
lymphocyte antigen-Immunoglobulin)-fusion proteins (of Boryung Pharm
(KR))), is not new and not inventive.
Because of my DE19925052 (and DE10162870) the following publications
of others, disclosing fusion proteins containing cell specific
recognition domains in order to direct immune cells against target,
preferably cancer cells, or fusion proteins containing cell specific
and cytotoxic domains, (as well as spacers and protease-sensitive
sites), are not new and not inventive: WO2007002905 and EP1909832
(“Antibody-Immune Cell Ligand Fusion Protein for Cancer Therapy” of
Joseph Rosenblatt (US), Khaled Tolba (US) and Seung-Uon Shin (US) at
the University of Miami, (claim 18 discloses also “a monocyte
receptor, a B-cell surface receptor, and/or a T cell surface
receptor”), US20070071759 (“Antibody-Immune Cell Ligand Fusion Protein
for Cancer Therapy” of and Seung-Uon Shin, Joseph Rosenblatt, Khaled
Tolba at University of Miami), WO2006083961 (“Targeted Polypeptides”
(according to the abstract “for treating, preventing, and/or
monitoring therapy for a B-cell proliferative disorder”) of Michael
Rosenblum (US), Lawrence Cheung (US) and Mi-Ae Lyu (US) at Reserch and
Development Foundation (US); especially the claims 1-14, whereby
claims 4,5,10 and 14 describe cytotoxic B-cell targeting fusion
proteins), EP1217070, WO02052022 and AU2002229675 (“Selective
cytotoxic fusion proteins” of Felicia Rosenthal, Ou Cao and Peter
Kulmburg at Cellgenix Technologie Transfer; claim 27 reveals “a
polypeptide comprising…receptor (IL-2 receptor), …spacer
and…ribonuclease…”, (fusion proteins according to my DE19925052A1
comprise a receptor (claim 5), nuclease (claim 21), and hinge/spacer
domain (11 in Fig.1, Fig.3 and Fig.5)), claim 1 of EP1217070 reveals
“…a fusion protein which comprises a first polypeptide capable of
binding to a cell surface receptor present on human cells and a second
polypeptide which is toxic to a human cell after internalization of a
said second polypeptide by the human cell”; this fusion protein is
revealed in claims 5,12 and 13 and Fig.1 of my DE19925052A1),
US20110071214 (“Methods and Compositions for the Treatment of Cancer”
of Allen Gregory John (AU), (also published as WO2009137872 and
CA2760041), especially claims 1,4,83 (single-chained antibody) and 88
(haematological cancer)), US200600228404 (“Compositions and methods
for treatment of hypertrophic tissues” of Daniel Anderson (US), Robert
Langer, Robert Padera, Weidan Peng and Janet Sawicki; especially
claims 24,42 (cytotoxic or cytostatic polypeptide), 48 and 100
(site-specific recombinase), 104 (toxins), (the according claims in my
DE19925052A1 are 5,1 and 21)), US20120269837 (“Substance binding human
IgG Fc Receptor IIb (Fc gamma RIIb)” of the Nobelist Robert Huber
(DE), Peter Sondermann (CH), Kerstin Wendt (DE), Chiara Cabrele (DE)
and Luis Moroder (DE); especially the claims 57, 60 (polypeptide of
claim 57 conjugated to Fc [gamma] RIIb or Fc (gamma) RIIa) and 73
(cancer); (see claim 5 of my DE19925052A1), US20120269837 is also
published as WO2005051999, US2008014141, PT1709073 and PL1709073 and
is not novel also because of my DE10160248, DE10202191 and
DE102005028619), US20120107301 (“Method of treating autoimmune disease
by inducing antigen presentation by tolerance inducing antigen
presenting cells” of Katherine Bowdish (US), Anke Kretz-Rommel (US),
and Naveen Dakappagari at Alexion Pharma (US), especially the claims
8,13 (an antibody/peptide construct as in claim 8 further comprising a
toxin linked to the antibody) and 14 (tumor cell toxin); US20120107301
is also published as WO2004091543, US20060257412, US20060280679 and
NZ577166 and is also not novel because of my DE10133071), WO2007048022
(“Antibody-polypeptide Fusion Proteins and Methods for Producing and
Using Same” of Anke Kretz-Rommel et al at Alexion Pharma; this fact
was also described in my blog http://cherkaskyoffers.blogspot.com/)
and US20110275120 (“Fusion Proteins with Cleavable Spacers and Uses
Thereof” of Shen Wei-Chiang (US) et al at University of Southern
California; also published as WO2008121898, US20080299612, US7956158
(which can be invalidated and withdrawn after re-examination with the
USPTO), JP2010522570 and EP2139318, which are not novel because of
claim 12 and Fig. 3 (11 (hinge or spacer) and 9 (protease sensitive
site), 9 and 11 in combination) of my DE19925052A1).
My anti-autoimmune inventions (DE19822406, DE10133071 (making for
example MBP-toxin disclosed in WO2011101870 “Fusion Proteins for the
Treatment of Multiple Sclerosis and other Autoimmune Disorders” of
Kollipara Koteswara Rao (IN) at Transgene Biotek Ltd (IN) not novel
and not inventive), and DE10160248) allow to cleave and/or to
remove/neutralize autoantibodies and destroy autoreactive cells,
especially autoreactive B and T cells. And my DE19951694 allows to
regenerate tissue(s) destroyed especially by autoimmune attacks. With
my DE10202191 (Method for isolation and manipulation of single
molecules) still unknown autoantigens (from autoantigen candidates)
can be identified (0034-0038 of my DE10202191). Based on the
autoantigen information, new anti-autoimmune fusion proteins according
to my DE19822406, DE10133071 and DE10160248 can be made.

My anti-viral inventions allow to combat viruses both inside the cells
(by using my cell-specific, cell-penetrating and blocking nucleic acid
(antiviral ribozyme or antisense RNA)- transportating fusion proteins
disclosed in my German patent DE19925052) and outside the cells by
using my invention of cell-traps for viruses (my invention DE19951694
from the year 1999).
DE19951694 is a multipurpose invention comprising genetically modified
cells, especially immune cells, which express, for example neural or
neurogenesis proteins (like NGF, BDNF and/or other neural proteins)
for (in vivo) immune cell-induced neurogenesis and neural regeneration
(claims 5 and 16 and description, column 5, lines 30-36) and these
genetically modified cells, preferably immune cells, express also, or
alternatively, myelinogenesis proteins for immune cell-induced
myelination as well as myogenesis proteins for immune cell-induced
regeneration of muscles (claim 14) and/or angiogenesis proteins for
immune cell-induced angiogenesis (claim 3).
Cell-traps for viruses express antiviral antisense RNA and/or
antiviral ribozymes (for netralizing or cleavage/destruction of viral
RNA or DNA) and receptors for viral recognition, (like CD4 for HIV,
see claim 11 of my DE19951694).
Fusion proteins and fusion protein complexes according to DE19925052
can recognize targeted cells, (already infected cells or cells, that
can be infected), through the recognition region, penetrate them and
internalize into them through the mebrane penetration domains (MPD) or
cell penetration peptides (CPP) and bring into cells molecules,
especially antiviral RNA (such as specifically cleaving ribozyme(s) or
specifically neutralizing antisense RNA).
Fusion proteins containing any random protein (to be transported into
a cell) and MPD (membrane penetration domain) or CPP (for membrane
penetration and internalization) are covered by my published
DE19925052A1 (claims 4, 5, 6, 11 and 12), DE19951694 (claims 4 and 9)
and DE10162867 in the claim 1.

Because of my patent publication DE10162867 (claim 1 discloses fusion
proteins comprising, i.e. containing membrane penetration domain and
any other region/domain), as well as my DE19951694 and DE19925052, the
following publications of others, disclosing fusion proteins
containing MPD or CPP, are not novel and not inventive:US20120135021
(”Cell Penetrating Peptides and Its Use Fused to Biomolecules With
Therapeutic Action” of Torens Madrazo; Isis del Carmen; (Ciudad de la
Habana, CU); Guerra Vallespi; Maribel (CU); Granadillo Rodriguez;
Milaid; (CU); Reyes Acosta; Osvaldo (CU); Acevedo Casto; (CU) and
Boris Ernesto; (CU)), KR20020074282 (”Cell-Transducible Catalase
Fusion Protein And The Use Theseof” of Choi Su Young (KR) et al; also
published as KR100495139), KR20020010445 (”Cell-Transducing HIV-1
TAT-Superoxide Dismutase Fusion Protein And Use Theseof” of Choi Su
Young et al), WO2011084061 (”CPP (Cell Penetrating Peptide) and Its
Uses” of Universitair Medisch Centrum St. Radboud (NL), Roland Brock
(DE) and Wouter Verdurmen (NL); especially claim 4 (”the cationic CPP
is selected from the group consiting of: a cationic CPP
peptidomimetic, an arginine-rich CPP, a guanidine-rich CPP
peptidomimetic, a CPP derived from the human milk protein
lactoferrin”) and claim 9 (”the CPP is used in combination with
another cancer therapy”)), MX2008008548 (”Peptides Useful As
Cell-Penetrating Peptides” of Roland Brock (DE), Rainer Fischer (DE),
Mariola Fotin-Mleczek (DE), Hansjoerg Hufnagel and Norbert Windhab at
Evonik Roehm GmbH; also published as WO2007076904, US20100061932,
SI1966240, KR20080091120 and JP2009521908), KR20100001091 (”Fusion
Peptides Introducing Antibody into Cells, and Cellular Imaging and
Targeted Drug Delivery System Using the Same” of Chung Sang Jeon (KR)
et al, at Korea Research Institute of Bioscience), CN102311500
(”Antiviral fusion protein and application therof” of Lei Yang et al.
at Hangzhou Normal University), KR20100006939 (”Method for
Reprogramming of Cells Using Fusion Protein Delivery” of Korea
Research Institute of Bioscience and Biotechnology, (named ”inventors”
are Koo Deog Bon (KR), Kim Jang Hwan (KR), Cho Yee Sook (KR), Lee Seok
Jae (KR), and Park Tae Jung (KR))), and WO2010010112 (”Construct and
Method for the Internalization of Cargo Molecules Into a Cell” of DKFZ
Krebsforschungszentrum (DE), Markus Moosmeier (DE), Felix Hoppe-Seyler
(DE) and Karin Hoppe-Seyler (DE), also published as EP2147683).

Viral genetic information, i.e. viral nucleic acids inside cells can
be also specifically cleaved by selective fusion proteins containing
nuclease (enzyme for cleaving nucleic acids). This invention is
disclosed in my published German patent document DE10162870 (from the
year 2001). Because of my patent publications DE19925052 A1 (claims 5
and 21) and DE10162870, (claim 1 disloses also fusion proteins
containing nuclease and any other region or domain), the following
publications of others, disclosing fusion proteins containing
nuclease, are not novel and not inventive: WO2012168304 (”Protein
Having Nuclease Activing, Fusion Proteins and Uses Thereof” of
Helmholtz Zentrum Muenchen (Helmholtz Zentrum Muenchen-Deutsches
Forschungszentrum Fuer Gesundheit und Umwelt GmbH (DE)) and Ralf
Kuehn (DE)), WO2012168910 (”Nuclease Fusion Protein And Use Thereof”
of BASF Plant Science Co GmbH (DE), BASF China Co LTD (CN), Ines
Fonfara (DE), Wolfgang Wende (DE) and Alfred Pingoud (DE)),
WO2012169916 (”Sequence-Specific Engineered Ribonuclease H and The
Method for Determining the Sequence Preference of DNA-RNA Hybrid
Binding Proteins” of Miedzynarodowy Inst. Biolog. Molekularnej i
Komorkowej (PL), Janusz Marek Bujnicki (PL) et al; this WO2012169916
is also not novel because of my DE10162867 covering nucleic acid
binding fusion proteins), US20090123972 (”Staphylococcal nuclease
fusion proteins for the production of recombinant peptides” of Canada
Natural Research Council, (named inventors are Su Zhengding (CA) and
Ni Feng (CA)), WO2011159369 (”Nuclease Activity of Tal Effector and
Foki Fusion Protein” of University of Iowa Research Foundation (US),
named inventors are Yang Bing (US) and Li Ting (US)), WO2012168304
(”Protein Having Nuclease Activity, Fusion Proteins and Uses Thereof”
of Helmholtz Zentrum Muenchen (DE) and Ralf Kuehn (DE)) and
WO2011154393 (”Fusion Proteins Comprising A DNA-Binding Domain of A
Tal Effector Protein And A Non-Specific Cleavage Domain Of A
Restriction Nuclease And Their Use” of Helmholtz Zentrum Muenchen
(DE), Ralf Kuehn (DE) et al; also not novel because of my DE10162867,
claim 3 (disclosing fusion proteins containing DNA binding
domain(s))).

Vaxil Presents My Inventions As Vaxil’s Own

Alexander Cherkasky

alexcherkasky@googlemail.com

My published German patent application DE19951694 (from the year 1999
(Filing date: October 27, 1999)), which damages and claims priority
worldwide, discloses also in the claims 4 and 9 fusion proteins
comprising random proteins of interest and membrane penetration
domains (MPD) as well as fusion proteins comprising random proteins of
interest and signal peptides, i.e. signal peptide domains. Thus these
fusion proteins can migrate in extracellular and intracellular space
(claim 4).
This my invention of fusion proteins comprising any protein and signal
peptide domain, disclosed in DE19951694, was descibed and
plagiaristically used by the Israeli company Vaxil (by Lior Carmon) in
its US20120177677 (”Antigen Specific Multi-Epitope-Based
Anti-infective Vaccines”), WO2011007359 and EP2453914 (from the years
2009 and 2010) and ”Antigen Specific Multi Epitope Vaccines”
(US20100074925 (claims 39, 57, 58), EP2089423, WO2008035350, CA2665816
and AU2007298494). In these publications Vaxil described ”peptide
vaccines including the signal peptide domain” (Abstract of
US20120177677 as well as claim 29 (”a vaccine comprising a peptide or
a recombinant polypeptide(!) consisting of at least one signal peptide
domain(!) of at least one target protein(!) of a intracellular(!)
pathogen”) and claim 36 (”restriction enzyme sites” were disclosed in
my DE19925052 A1, claims 9, 12 and 20 (for therapeutic use)) and claim
42 of Vaxil’s US20120177677). But as mentioned above these
descriptions of Vaxil (Vaxil BioTherapeutics Ltd. (TASE:VAXL)) are not
new and not inventive because of my DE19951694.
Investors of Vaxil must know this information, because this key
intellectual property of Vaxil can be lost (for example, patents will
not be granted or if granted by errors of examiners, the patents can
be rejected after reexamination with the United States Patent and
Trademark Office (USPTO)), and thus products/product canditates of
Vaxil can not be protected from competitors.